Updated March 11, 2024:
For added information, visit BC Government Your Voice page
The province of BC is inviting input from the public coverage for Maviret ® (glecaprevir-pibrentasvir), a drug that can be used to treat hepatitis C in pediatric patients between the ages of 3 and 11. Taken in granule format, this drug is the only existing treatment for children under the age of 12, or who weigh less than 45 kg.
Having access to this treatment may allow children to clear the virus, as well as the stigma that often goes along with hepatitis C.
PAN will be completing a survey as a patient group, as will BC Hepatitis Network. Together, we encourage other PAN members who support people with lived and living experience of hepatitis C to consider registering as a patient group and completing the survey – becoming a recognized patient group is an easy process. If you would like to share your experiences or stories, you can contact Deb Schmitz at BC Hepatitis Network.
Individuals (patients, parents, caregivers) can also complete a survey and do not need to register. The deadline for completing the survey is Tuesday, March 26, 2024, at 11:59 PM.
BC residents may complete a Your Voice survey if they:
- Have the medical condition the drug would treat, or
- Are a caregiver for someone with the condition the drug would treat, or
- Represent a patient group for BC patients with the condition the drug would treat.
PharmaCare regularly reviews drugs to decide whether to cover them. In making a coverage decision, PharmaCare considers a drug’s safety, how well it works, how much it costs, and how it compares to other, similar drugs. Another consideration is feedback provided by people with experience using the product under review and/or with the condition it would treat.
If you’re interested in learning more about how to add your thoughts, visit Your Voice page to learn about the process, see sample surveys, and submit your views. Scroll to Glecaprevir-Pibrentasvir (Maviret®) and read the pdf on medication information, then click the link on the drug name.